News on the Division of Blood Diseases and Resources
When it comes to convalescent plasma for the treatment of COVID-19, early intervention appears to make a difference for some outpatients.
|
NHLBI in the Press
Nearly 90% of COVID-19 patients who qualified for but did not receive ECMO (extracorporeal membrane oxygenation) due to a shortage of devices during the pandemic died in the hospital.
|
NHLBI in the Press
Researchers are reporting new evidence that pregnant women who are taking hydroxyurea for sickle cell disease may face more adverse pregnancy outcomes than those who are not taking the drug.
|
NHLBI in the Press
An experimental gene therapy approach for treating sickle cell disease shows promise for eliminating painful crises that are associated with the condition, according to interim findings from a clinical trial.
|
Research Feature
NIH research continues to evaluate how blood thinners and anti-inflammatory medications may strengthen recovery at different points in the life of the virus W. Keith Hoots, M.D., director of the Division of Blood Disorders and Resources (DBDR) at the National Heart, Lung, and Blood Institute (NHLBI), shares insight into how treatments that break up...
|
NHLBI in the Press
The final results of the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) demonstrate that COVID-19 convalescent plasma did not prevent disease progression in a high-risk group of outpatients with COVID-19.
|
Research Feature
Every two seconds someone in the U.S. needs blood. And according to the American Red Cross, a single donation can save up to three lives. On June 14, the National Heart, Lung, and Blood Institute (NHLBI) joins the World Health Organization (WHO) in observing World Blood Donor Day. Simone Glynn, M.D., M.P.H., chief of the Blood Epidemiology and...